Drug discovery in the next decade: Innovation needed ASAP

Drug Discovery Today

Volumn 17, Issue SUPPL., 2012, Pages

  Bennani, Youssef L ^a  

^a VERTEX PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALISKIREN; AMLODIPINE PLUS ATORVASTATIN; ARIPIPRAZOLE; ATORVASTATIN; BEVACIZUMAB; BORTEZOMIB; BUDESONIDE; CASPOFUNGIN; CETIRIZINE; CLOPIDOGREL; CYCLOSPORIN; DAPTOMYCIN; DOCETAXEL; ENOXAPARIN; ESOMEPRAZOLE; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; FEXOFENADINE; FLUINDOSTATIN; LANSOPRAZOLE; LENALIDOMIDE; LEUPRORELIN; LOPINAVIR; MODAFINIL; MOMETASONE FUROATE; MONTELUKAST; OLANZAPINE; OMEPRAZOLE; OSELTAMIVIR; OXYCODONE; PANTOPRAZOLE; QUETIAPINE; RABEPRAZOLE; RAPAMYCIN; RECOMBINANT ERYTHROPOIETIN; RISPERIDONE; RITONAVIR; ROSUVASTATIN; SILDENAFIL; SIMVASTATIN; TACROLIMUS; TELAPREVIR; TERAZOSIN; UNINDEXED DRUG; VALPROATE SEMISODIUM; ZIPRASIDONE;

BIOLOGY; CHEMISTRY; DRUG INDUSTRY; DRUG INFORMATION; DRUG RESEARCH; DRUG STRUCTURE; REVIEW;

EID: 84855829699     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2011.12.007     Document Type: Review

References (106)

1. B. Hughes 2009 FDA drug approvals Nat. Rev. Drug Discov. 9 2010 89 92
2. J. Dorren Corbett Drug approvals slipped in 2010 Wall Street J. 2010
3. D. Cavalla, and R. Minhas Does R&D pay? Drug Discov. Today 15 2010 230
4. M. Williams Productivity shortfalls in drug discovery: contributions from the preclinical sciences? J. Pharmacol. Exp. Ther. 336 2011 3 8
5. G.M. Whitesides, and J. Deutch Let's get practical Nature 469 2011 21 22
6. T. Peters The Circle of Innovation: You Can't Shrink Your Way to Greatness 1999 Vintage Books
7. M. Ratner Crossing the line Nat. Biotechnol. 28 2010 1232 1235
8. C. Terwiesch, and K. Ulrich Innovation Tournaments: Creating and Selecting Exceptional Opportunities 2009 Harvard Business School Press
9. J.A. DiMassi The price of innovation: new estimates of drug development costs J. Health Econ. 22 2003 151 185
10. J.A. DiMassi, and L.B. Faden Competitiveness in follow-on R&D: a race or imitation Nat. Rev. Drug Discov. 10 2011 23 27
11. O. Hammer Lessons learned from Sanofi-Aventis's phase III failure Seeking-Alpha 2011 http://seekingalpha.com/article/250527-lessons-learned-from- sanofi-aventis-s-phase-iii-failure
12. R.A. Galemmo Jr. Memorial issue in honor of Dr. Paul A.J. Janssen preface J. Med. Chem. 48 2005 1686
13. K.C. Nicolaou The art and science of total synthesis at the dawn of the twenty-first century Angew. Chem. Int. Ed. 39 2000 44 122
14. E.M. Driggers The exploration of macrocycles for drug discovery: an underexploited structural class Nat. Rev. Drug Discov. 7 2008 608 624 (Pubitemid 351927725)
15. M.A. Clark Design, synthesis and selection of DNA-encoded small-molecule libraries Nat. Chem. Biol. 5 2009 647 654
16. R. Noyori Synthesizing our future Nat. Chem. 1 2009 5
17. S.J. Teague The design of leadlike combinatorial libraries Angew. Chem. Int. Ed. 38 1999 3743 3748 (Pubitemid 30022004)
18. G. Festel Outsourcing chemical synthesis in the drug discovery process drug Drug Discov. Today 16 2011 237
19. C.A. Lipinski Drug-like properties and the causes of poor solubility and poor permeability J. Pharmacol. Toxicol. Methods 44 2000 235 249 (Pubitemid 32239479)
20. P.D. Leeson, and B. Springthorpe The influence of drug-like concepts on decision-making in medicinal chemistry Nat. Rev. Drug Discov. 6 2007 881 890 (Pubitemid 350042396)
21. T.W. Johnson Using the golden triangle to optimize clearance and oral absorption Bioorg. Med. Chem. Lett. 19 2009 5560 5564
22. Y.W. Alelyunas Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate Bioorg. Med. Chem. Lett. 20 2010 7312 7316
23. F. Milletti, and A. Vulpetti Predicting polypharmacology by binding site similarity: from kinases to the protein universe J. Chem. Inf. Model. 50 2010 1418 1431
24. E. Lounkine SARANEA: a freely available program to mine structure-activity and structure-selectivity relationship information in compound data sets J. Chem. Inf. Model. 50 2010 68 78
25. D.K. Agrafiotis SAR Maps: a new visualization technique for medicinal chemists J. Med. Chem. 50 2007 5926 5937
26. M. Michino Community-wide assessment of GPCR structure modeling and ligand docking: GPCR Dock 2008 participants Nat. Rev. Drug Discov. 8 2009 455 463
27. A.M. Wassermann Activity landscape representations for SAR analysis J. Med. Chem. 53 2010 8209 8223
28. C.R. Gardner Drugs as materials: valuing physical form in drug discovery Nat. Rev. Drug Discov. 3 2004 926 934 (Pubitemid 39529930)
29. Connelly, P.R. et al. (2010) The integrated local CMC service provider: toward a deep economy of pharmaceuticals. Pharmaceut. Outsourcing 3091
30. J. Inglese, and D.S. Auld High throughput screening techniques: applications in chemical biology T.P. Begley, Wiley Encyclopedia of Chemical Biology 2009 Wiley-Interscience http://www.sciencedirect.com/science/article/ pii/S1367593110000463
31. B.K. Wagner, and P.A. Clemons Connecting synthetic chemistry decisions to cell and genome biology using small-molecule phenotypic screening Curr. Opin. Chem. Biol. 13 2009 539 548
32. G.C. Terstappen Target deconvolution strategies in drug discovery Nat. Rev. Drug Discov. 6 2007 891 903 (Pubitemid 350042397)
33. R. Raddatz Allosteric approaches to the targeting of G-protein-coupled receptors for novel drug discovery: a critical assessment Biochem. Pharmacol. 74 2007 383 391 (Pubitemid 46963242)
34. P.J. Conn Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders Nat. Rev. Drug Discov. 8 2009 41 54
35. K. Leach Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology Trends Pharmacol. Sci. 28 2007 382 389 (Pubitemid 47087967)
36. L.T. May Allosteric modulation of G protein-coupled receptors Annu. Rev. Pharmacol. Toxicol. 47 2007 1 51 (Pubitemid 46277033)
37. T. Kenakin Allosteric agonist modulators J. Recept. Signal Transduct. Res. 27 2007 247 259 (Pubitemid 47450770)
38. T. Kenakin G-protein coupled receptors as allosteric machines Receptors Channels 10 2004 51 60 (Pubitemid 39023202)
39. T. Kenakin New concepts in drug discovery: collateral efficacy and permissive antagonism Nat. Rev. Drug Discov. 4 2005 919 927 (Pubitemid 41637694)
40. F.T. Horrigan, and R.W. Aldrich Coupling between voltage sensor activation, Ca2+ binding and channel opening in large conductance (BK) potassium channels J. Gen. Physiol. 120 2002 267 305 (Pubitemid 35014730)
41. F.T. Horrigan Allosteric voltage gating of potassium channels. I. Mslo ionic currents in the absence of Ca2+ J. Gen. Physiol. 114 1999 277 304 (Pubitemid 29380155)
42. J. Monod On the nature of allosteric transitions: a plausible model J. Mol. Biol. 12 1965 88 118
43. J.L. Klepeis Long-timescale molecular dynamics simulations of protein structure and function Curr. Opin. Struct. Biol. 19 2009 120 127
44. D.M. Korzhnev, and L.E. Kay Probing invisible, low-populated states of protein molecules by relaxation dispersion NMR spectroscopy: an application of protein folding Acc. Chem. Res. 41 2008 442 451
45. K. Henzler-Wildman, and D. Kern Dynamic personalities of proteins Nature 450 2007 964 972 (Pubitemid 350273626)
46. D.J. Selkoe Folding proteins in fatal ways Nature 426 2003 900 904 (Pubitemid 38056883)
47. F. Chiti, and C.M. Dobson Protein misfolding, functional amyloid, and human disease Annu. Rev. Biochem. 75 2006 333 366 (Pubitemid 44118036)
48. J.A. Wells, and C.L. McClendon Reaching for high-hanging fruit in drug discovery at protein-protein interfaces Nature 450 2007 1001 1009 (Pubitemid 350273630)
49. A.D. Ebert, and C.N. Svendsen Human stem cells and drug screening: opportunities and challenges Nat. Rev. Drug Discov. 9 2010 367 372
50. Y. Chudnovsky Use of human tissue to assess the oncogenic activity of melanoma-associated mutations Nat. Genet. 37 2005 745 749 (Pubitemid 41754892)
51. M. Rowland Physiologically-based pharmacokinetics in drug development and regulatory science Annu. Rev. Pharmacol. Toxicol. 51 2010 45 73
52. W. Loscher Valproate, Milestones in Drug Therapy Series 1999 Springer
53. M. Garcia-Calvo The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1) Proc. Natl. Acad. Sci. U. S. A. 102 2005 8132 8137 (Pubitemid 40800055)
54. R.A. Kloner Effects of sildenafil in patients with erectile dysfunction taking antihypertensive therapy Am. J. Hypertens. 14 2001 70 73 (Pubitemid 32105922)
55. B.P. Zambrowicz, and A.T. Sands Knockouts model the 100 best-selling drugs: will they model the next 100? Nat. Rev. Drug Discov. 2 2003 38 51 (Pubitemid 37361623)
56. F.M. Goodsaid Voluntary exploratory data submission to the FDA and the EMA: experience and impact Nat. Rev. Drug Discov. 9 2010 435 445
57. A. Terzic, and C. Perez-Terzic Channelopathies: decoding disease pathogenesis Sci. Translat. Med. 2 2010 42ps37
58. S.C. Strom Chimeric mice with humanized liver: tools for the study of drug metabolism, excretion, and toxicity Hepatocytes: Methods Protoc. 640 2010 491 509
59. N. Legrand Humanized mice for modeling human infectious disease: challenges, progress, and outlook Cell Host Microbe 6 2009 5 9
60. R. Van Duyne The utilization of humanized mouse models for the study of human retroviral infections Retrovirology 6 2009 76 94
61. B. Zhang Mouse models with human immunity and their application in biomedical research J. Cell. Mol. Med. 13 2009 1043 1058
62. C. Cheung, and F.J. Gonzalez Humanized mouse lines and their application for prediction of human drug metabolism and toxicological risk assessment J. Pharmacol. Exp. Therapeut. 327 2008 288 299
63. F. Macchiarini Humanized mice: are we there yet? J. Exp. Med. 202 2005 1307 1311
64. A.L. Hopkins Network pharmacology: the next paradigm in drug discovery Nat. Chem. Biol. 4 2008 682 690
65. S.J. Shukla The future of toxicity testing: a focus on in vitro methods using a quantitative high-throughput screening platform Drug Discov. Today 15 2010 997 1007
66. G.D. Prestwich Evaluating drug efficacy and toxicology in three dimensions: using synthetic extracellular matrices in drug discovery Acc. Chem. Res. 41 2007 139 148
67. J.D. Hughes Drug properties associated with in vivo toxicological outcomes Bioorg. Med. Chem. Lett. 18 2008 4872 4875
68. B. Munos Lessons from 60 years of pharmaceutical innovation Nat. Rev. Drug Discov. 8 2009 959 968
69. S.M. Paul How to improve R&D productivity: the pharmaceutical industry's grand challenge Nat. Rev. Drug Discov. 9 2010 203 214
70. P. Agarwal, and D.B. Searls Can literature analysis identify innovation drivers in drug discovery? Nat. Rev. Drug Discov. 8 2009 865 878
71. T. Hoffmann, and C. Bishop The future of discovery chemistry: quo vadis? Academic to industrial: the maturation of medicinal chemistry to chemical biology Drug Discov. Today 15 2010 260
72. R.S. Root-Bernstein Discovering, Inventing and Solving Problems at the Frontiers of Scientific Knowledge 1989 Harvard University Press Chapter 8, pp. 410-412
73. E. Perola An analysis of the binding efficiencies of drugs and their leads in successful drug discovery programs J. Med. Chem. 53 2010 2986 2997
74. E. Osono Extreme Toyota: Radical Contradictions that Drive Success at the World's Best Manufacturer 2008 John Wiley & Sons
75. Z. Hua Integration TRIZ with problem-solving tools: a literature review from 1995-2006 Int. J. Bus. Innovat. Res. 2006 111 128 http://en.wikipedia.org/ wiki/TRIZ
76. S. Hamm Tech Innovations for Tough Times 2008 Bloomberg Businessweek
77. A.T. Chadwick, and M.D. Segall Overcoming psychological barriers to good discovery decisions Drug Discov. Today 15 2010 561
78. M.I. Ecemis A drug candidate design environment using evolutionary computation IEEE Trans. Evol. Comput. 12 2008 591 603
79. E. Bonabeau Don't Trust Your Gut 2003 Harvard Business Review
80. C. Jensen Aliskiren: the first renin inhibitor for clinical treatment Nat. Rev. Drug Discov. 7 2008 399 410 (Pubitemid 351619112)
81. K.M. Giacomini Membrane transporters in drug development Nat. Rev. Drug Discov. 9 2010 215 236
82. Y.W. Chin Drug discovery from natural sources AAPS J. 8 2006 E239
83. B. Haefner Drugs from the deep: marine natural products as drug candidates Drug Discov. Today 8 2003 536 544 (Pubitemid 36773671)
84. R. Bade Characteristics of known drug space; natural products, their derivatives and synthetic drugs Eur. J. Med. Chem. 45 2010 5646 5652
85. F.E. Koehn, and G.T. Carter The evolving role of natural products in drug discovery Nat. Rev. Drug Discov. 4 2005 206 220 (Pubitemid 40372555)
86. M.H. Potashman, and M.E. Duggan Covalent modifiers: an orthogonal approach in drug design J. Med. Chem. 52 2009 1231 1246
87. J.W. Clader The discovery of ezetimibe: a view from outside the receptor J. Med. Chem. 47 2004 1 9 (Pubitemid 38040483)
88. J. Adams Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids Bioorg. Med. Chem. Lett. 8 1998 333 338 (Pubitemid 28072702)
89. R.B. Perni Preclinical profile of Telaprevir, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease Antimicrob. Agents Chemother. 50 2006 899 909 (Pubitemid 43327793)
90. F. Maltais In vitro and in vivo isotope effects with hepatitis C protease inhibitors: enhanced plasma exposure of deuterated Telaprevir versus Telaprevir in rats J. Med. Chem. 52 2009 7993 8001
91. A. Badaru Sequential comparisons of one-month and three-month depot leuprolide regimens in central precocious puberty J. Clin. Endocrinol. Metab. 91 2006 1862 1867
92. J.N. Steenbergen Daptomycin: a lipopeptide antibiotic for the treatment of serious gram-positive infections J. Antimicrob. Chemother. 55 2005 283 288 (Pubitemid 40425449)
93. T.J. Walsh Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia N. Engl. J. Med. 351 2004 1391 1402
94. C. Vézina Rapamycin (AY-22,989), a new antifungal antibiotic J. Antibiot. 28 1975 721 726
95. B. Rubio-Viqueira, and M. Hidalgo Targeting mTOR for cancer treatment Curr. Opin. Investig. Drugs 7 2006 501 512 (Pubitemid 43891028)
96. S. Singhal Antitumor activity of thalidomide in refractory multiple myeloma N. Engl. J. Med. 341 1999 1565 1571
97. H. Lepor The efficacy and safety of terazosin in the treatment of BPH Prostate 18 1991 345 355
98. Z. Itoh Gastrointestinal motor-stimulating activity of macrolide antibiotics and analysis of their side effects on the canine gut Antimicrob. Agents Chemother. 26 1984 863 869 (Pubitemid 15181380)
99. J.C. Brown Motilin, a gastric motor activity stimulating polypeptide: the complete amino acid sequence Can. J. Biochem. 51 1973 533 537
100. S.D. Feighner Receptor for motilin identified in the human gastrointestinal system Science 284 1999 2184 2188 (Pubitemid 29297480)
101. Feighner, S.D. et al. (1999) Cloning and identification of the human motilin receptor isoforms. PCT Int. Appl. WO 9964436 A1 19991216
102. M. Gladwell Outliers 2008 Little, Brown & Co.
103. W.C. Kim, and R. Mauborgne Blue Ocean Strategy: How to Create Uncontested Market Space and Make Competition Irrelevant 2005 Harvard Business Press
104. L.J.S. Knutsen Drug discovery management, small is still beautiful: why a number of companies get it wrong Drug Discov. Today 2011 10.1016/J.DRUDIS.2011. 04.002
105. Lehrer, J. (2010) Accept defeat: the neuroscience of screwing up. Wired Mag. http://www.wired.com/magazine/2009/12/fail-accept-defeat/
106. D.E. Clark, and C.G. Newton Outsourcing lead optimisation - the quiet revolution Drug Discov. Today 9 2004 492 500 (Pubitemid 38626086)